• By ICR Secretariat
  • Posted Thursday, June 30, 2022

UCB lowers 2022 profit expectations amid Ukraine war, rising costs

https://www.fiercepharma.com/pharma/ucb-updates-2022-financial-guidance-citing-external-headwinds

Generic competition, a complete response letter, a new acquisition and external pressures have created a perfect storm for UCB, leading the company to reduce its profit forecast for 2022.